Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

10/04/2019 10th Anniversary of the MELiSSA Pilot Plant: travelling to Mars is in progress near the Barcelona Synchrotron Park 25/03/2019 Barcelona Synchrotron Park Sponsors the 9th Ideas Generation Program 08/03/2019 The Barcelona Synchrotron Park aims to host a university residence 01/03/2019 Delegates of the Mobile World Congress discover the park 22/02/2019 Hub b30 takes off 16/02/2019 SENER: wind, sun and moon
4 5 6 7 8 9 10 11 12 13 14